Engineered immune cells target tough childhood leukemia in new trial
NCT ID NCT07244406
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This phase 2 trial tests an experimental treatment called Senl_B19 CAR-T cells in people aged 3 to 25 whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called CD19. The main goal is to see how many patients achieve a complete or partial remission three months after treatment, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact
Conditions
Explore the condition pages connected to this study.